Anti-PD-1 antibodies are beneficial for patients with R/M-HNSCC in terms of prolonged survival, but biomarkers are needed that can predict the response to ICI therapy and the occurrence of irAEs before starting treatment. Here, PDCD1 is linked to head and neck squamous cell carcinoma.